Successful Management of Drooling with Botulinum Toxin A in Neurologically Disabled Children

Abstract

Objectives

The present study investigates the effect of topical injections of botulinum toxin A into the cephalic salivary glands of children with chronic hypersalivation due to neurodegenerative diseases.

Methods

Five children with hypersalivation due to severe neurological diseases received, under ultrasound guidance, a total of 50 - 65 units of botulinum toxin A (Botox®) into the parotid and submandibular glands on both sides. All injections were tolerated without local anaesthesia. Before and 1, 2, 4, 8 and 12 weeks after toxin injection, salivary flow rates and the concentrations of total protein, alpha-amylase, acid phosphatase, kallikrein, and immunoglobulin A were measured in the secretions; simultaneously, the patients were clinically examined with regard to severity of symptoms, and their salivary glands were subjected to ultrasound study.

Results

A distinct improvement of symptoms within the first 2 weeks following toxin administration were reported by the parents. Sialometry revealed considerably reduced flow rates but sialochemistry showed an increase of amylase activity. Ultrasound examination did not reveal any changes of the salivary parenchyma, and side-effects were absent.

Conclusions

Treatment of drooling by topical injection of botulinum toxin A into the salivary glands is a reliable and also side-effect-free therapeutic option for children with neurological disorders. All children involved in our study experienced a distinct improvement of their quality of life.

Key words

Botulinum Toxin A - Salivary Glands - Children - Neurologic Diseases - Drooling

References

• 1 Arnold H G, Gross C W. Transtympanic neurectomy: a solution to drooling problems.  Dev Med Child Neurol. 1977;  19 509-513
• 2 Beuche W, Arglebe C, Laskawi R. Quantitative reduction of saliva production in two ALS patients with intraglandular injections of botulinum toxin.  Neurol Psychiatry Brain Res. 2000;  8 23-26
• 3 Bushara K O. Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment - botulinum toxin A injections of the parotid glands.  Med Hypotheses. 1997;  48 337-339
• 4 Crysdale W S, Raveh E, McCann C, Roske L, Kotler A. Management of drooling in individuals with neurodisability: a surgical experience.  Dev Med Child Neurol. 2001;  43 379-383
• 5 Ellies M, Laskawi R, Götz W, Arglebe C, Tormählen G. Immunohistochemical and morphometric investigations of the influence of botulinum toxin on the submandibular gland of the rat.  Eur Arch Otorhinolaryngol. 1999;  256 148-152
• 6 Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C. Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies.  J Oral Maxillofac Surg. in press; 
• 7 Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C, Beuche W. Botulinum toxin to reduce saliva flow: selected indications for ultrasound-guided toxin application into salivary glands.  Laryngoscope. 2002;  112 82-86
• 8 Ellies M, Laskawi R, Rohrbach-Volland S, Rödel R, Beuche W. Blocking of secretion in exocrine glands of the head and neck area with botulinum toxin A. Therapeutic option in the treatment of rare diseases.  HNO. 2001;  49 807-813
• 9 Ellies M, Laskawi R, Schütz S, Rohrbach-Volland S. Immunohistochemical evidence of nNOS and changes after intraglandular application of botulinum toxin A in cephalic salivary glands of adult rats.  Eur Arch Otorhinolaryngol. 2001;  258 317
• 10 Ellies M, Laskawi R, Tormählen G, Götz W. The effect of local injection of botulinum toxin A on the parotid gland of the rat. An immunohistochemical and morphometric study.  J Oral Maxillofac Surg. 2000;  58 1251-1256
• 11 Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I, Reiners C, Toyka K V. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis.  J Neurol Neurosurg Psychiatry. 2000;  69 121-123
• 12 Jongerius P H, Rooteveel J J, van den Hoogen F, Joosten F, van Hulst K, Gabreëls F JM. Botulinum toxin A: a new option for treatment of drooling in children with cerebral palsy. Presentation of a case series.  Eur J Pediatr. 2001;  160 509-512
• 13 Laskawi R, Drobik C, Schönebeck C. Up-to-date report of botulinum toxin treatment in patients with gustatory sweating.  Laryngoscope. 1998;  108 381-384
• 14 Mann A C. Localised autonomic failure due to botulinum toxin injection.  J Neurol Neurosurg Psychiatry. 1994;  57 1320
• 15 Mullins W M, Gross C W, Moore J M. Long-term follow-up of tympanic neurectomy for sialorrhea.  Laryngoscope. 1979;  89 1219-1223
• 16 Pal P K, Calne D B, Calne S, Tsui J KC. Botulinum toxin A as treatment for drooling saliva in PD.  Neurology. 2000;  54 244-247
• 17 Porta M, Gamba M, Bertacci G, Vaj P. Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injections in patients with neurological disorders.  J Neurol Neurosurg Psychiatry. 2001;  70 538-540
• 18 Suskind D L, Tilton A. Clinical study of botulinum A toxin in the treatment of sialorrhea in children with cerebral palsy.  Laryngoscope. 2002;  112 73-81